Skip to Main Content Go to Sitemap
SickKids

Sumit Gupta

Title: Staff Oncologist and Clinician Investigator, Division of Haematology/Oncology
Designations: MD, PhD, FRCPC
Email: Sumit.gupta@sickkids.ca
Alternate Contact Name: Maria Locke
Alternate Phone: 416-813-7654 ext. 224638
U of T Positions: Associate Professor, Department of Paediatrics, Institute for Health Policy, Management & Evaluation, and Institute of Medical Sciences

Research Positions

Associate Scientist
Child Health Evaluative Sciences

Biography

Dr. Sumit Gupta is a Staff Oncologist and Clinician Investigator at SickKids, an Associate Professor at both the Faculty of Medicine and the Institute for Health Policy, Management and Evaluation at the University of Toronto, and an Adjunct Scientist with the Cancer Research Program at the Institute for Clinical Evaluative Sciences. He completed a PhD in Clinical Epidemiology from the University of Toronto, during which time he was supported by a CIHR (Canadian Institutes of Health Research) Fellowship Award. He is one of the Assistant Chairs of the Lancet Oncology Commission on Sustainable Paediatric Cancer Care in low- and middle-income countries. Dr. Gupta has worked extensively with pediatric oncologists and policymakers throughout Latin America, the Caribbean, and India. He currently holds grant funding from The Garron Family Cancer Centre, CIHR and the Terry Fox Research Institute.

Research

Dr. Gupta’s main research goal is to identify and improve the outcomes of vulnerable subpopulations of children with cancer. To this end, he currently has two main lines of research. The first involves using health administrative data to answer important clinical and policy-relevant questions. Examples include building a detailed population-based database of all Ontario adolescents and young adults (AYA) with cancer, or identifying the mental health care use of childhood cancer survivors and their family members. His second main area of research involves collaboration with international partners to improve the outcomes for children with cancer in low- and middle-income countries (LMICS). He is the Associate Chair of the Lancet Oncology Commission on sustainable pediatric cancer care, which built an investment case for childhood cancer treatment in LMICS. He is also Chair of the Unit for Policy and Economics Research in Childhood Cancer (PERCC), with collaborations in multiple locations including Chile and Ghana. He is currently the co-chair of the Children’s Oncology Group clinical trial for children with acute lymphoblastic leukemia, AALL1731.

Education

Degrees

  • 1997–2001: Bachelor of Science (Hons), Life Sciences, Queen’s University, Kingston, ON
  • 2001–2005: Doctor of Medicine (Hons), Faculty of Medicine, University of Toronto, Toronto, ON
  • 2010–2014: PhD, Clinical Epidemiology, Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON

Postgraduate and Specialty Training

  • 2005–2008: Paediatric Resident, The Hospital for Sick Children, University of Toronto, Toronto, ON
  • 2008–2011: Paediatric Hematology/Oncology Subspecialty Resident, The Hospital for Sick Children, University of Toronto, Toronto, ON
  • 2010–2013: Chief Fellow, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON
  • 2010–2014: Clinician Investigator Program, Faculty of Medicine, University of Toronto 

Achievements

  • 2019: Conquer Cancer Foundation/Jim Nachman ASCO (American Society of Clinical Oncology) Junior Faculty Award in Pediatric Oncology - American Society of Clinical Oncology

Publications

  1. Gupta S, Aitken J, Bartels U, Bhakta N, Bucurenci M, Brierley J, De Camargo B, Chokunonga E, Clymer J, Coza D, Fraser C, Fuentes-Alabi S, Gatta G, Gross T, Jakab Z, Kohler B, Kutluk T, Moreno F, Nakata K, Nur S, Parkin M, Pole J, Poynter JN, Pritchard-Jones K, Ramirez O, Renner L, Steliarova-Foucher E, Sullivan M, Swaminathan R, Van Eycken L, Vora T, Frazier AL. Development of the Lyon paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto paediatric cancer stage guidelines. Lancet Oncol. Accepted May 2020. Impact factor 35.386 PA  
  2. Gupta S, Wang C, Raetz EA, Schore RJ, Salzer WL, Larsen EC, Maloney KW, Mattano LA Jr, Carroll WL, Winick NJ, Hunger SP, Loh ML, Devidas M. Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the Children’s Oncology GroupClin Oncol. 2020 Jun;38(17):1897-1905. Impact factor 35.386  PA 
  3. Beyea JA, Lau C, Cooke B, Hall S, Nathan PC, Gupta SLong-term incidence and predictors of significant hearing loss requiring hearing assistive devices among childhood cancer survivors: A population-based studyClin OncolEpub ahead of print 2020 May 28. Impact factor 35.386 SRI 
  4. Atun R, Bhakta N, Denburg A, Frazier L, Friedrich P, Gupta S, Lam CG, Ward ZJ, Yeh JM, Allemani C, Coleman MP, Di Carlo V, Loucaides E, Fitchett E, Girardi F, Horton SE, Bray F, Steliarova-Foucher E, Sullivan R, Aitken JF, Banavali S, Binagwaho A, Alcasabas P, Antillon F, Arora RS, Barr Rd, Bouffet E, Challinor J, Fuentes-Alabi S, Gross T, Hagander L, Hoffman RI, Herrera C, Kutluk T, Marcus KJ, Moreira C, Pritchard-Jones K, Ramirez O, Renner L, Robison LL, Shalkow J, Sung L, Yeoh A, Rodriguez-Galindo C. Sustainable care for children with cancer: A Lancet Oncology CommissionThe Lancet Oncology. 2020 Apr;21(4):e185-224. C 
  5. Van Warmerdam J, Sutradhar R, Kurdyak P, Lau C, Pole JD, Nathan PC, Gupta SLong-term mental health outcomes in mothers and siblings of children with cancer: A population-based matched cohort studyClin Oncol. 2020 Jan;38(1): 51-62. Impact factor 26.303 SRI

See a full list of Sumit Gupta's publications

Funding

  • Canadian Institutes of Health Research (CIHR)
  • C17 Research Network
  • Terry Fox Research Institute
  • Pediatric Oncology Group of Ontario (POGO)
  • Canadian Cancer Society Research Institute (CCSRI) 
Back to Top